Holen Sie sich die Stockscreener-App
224.77
0.08%
-0.18
Handel nachbörslich:
224.75
-0.02
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$224.95
Offen:
$226.01
24-Stunden-Volumen:
4.57M
Relative Volume:
0.72
Marktkapitalisierung:
$397.12B
Einnahmen:
$62.82B
Nettoeinkommen (Verlust:
$3.60B
KGV:
110.87
EPS:
2.0274
Netto-Cashflow:
$19.98B
1W Leistung:
-0.08%
1M Leistung:
+10.84%
6M Leistung:
+0.35%
1J Leistung:
+17.37%
1-Tages-Spanne:
$224.04
$227.55
1-Wochen-Bereich:
$221.16
$230.47
52-Wochen-Spanne:
$181.73
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
224.77 | 397.44B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,160.95 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
238.33 | 574.10B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
120.76 | 294.13B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.92 | 282.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com
AbbVie Loses Colorado 340B Drug Pricing Law Challenge - Law360
AbbVie: Growth-Pharma Profile At A Value-Pharma Price (NYSE:ABBV) - Seeking Alpha
Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225 - Yahoo Finance
Is AbbVie Inc. (ABBV) A Good Stock To Buy Now? - Insider Monkey
Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026? - TradingView
Zions Bancorporation National Association UT Sells 12,395 Shares of AbbVie Inc. $ABBV - MarketBeat
M Holdings Securities Inc. Takes Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie, Devon Energy And More On CNBC's 'Final Trades' - Benzinga
AbbVie Inc. $ABBV Shares Acquired by Wellspring Financial Advisors LLC - MarketBeat
Saturna Capital Corp Purchases 31,143 Shares of AbbVie Inc. $ABBV - MarketBeat
Smithbridge Asset Management Inc. DE Buys 18,364 Shares of AbbVie Inc. $ABBV - MarketBeat
Signet Private Wealth LLC Invests $1.20 Million in AbbVie Inc. $ABBV - MarketBeat
Townsquare Capital LLC Has $6.98 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Illinois Municipal Retirement Fund Lowers Position in AbbVie Inc. $ABBV - MarketBeat
Janney Montgomery Scott LLC Grows Position in AbbVie Inc. $ABBV - MarketBeat
Dorsey & Whitney Trust CO LLC Reduces Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. stock (US00287Y1091): investors eye Skyrizi/Humira dynamics after recent data update - AD HOC NEWS
Final Trades: AbbVie, Devon Energy and the 2-Year and 10-Year Treasuries - CNBC
Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics - AbbVie News Center
AbbVie's migraine drug cleared for migraine attacks on NHS - pharmaphorum
Stonebrook Private Inc. Sells 8,844 Shares of AbbVie Inc. $ABBV - MarketBeat
9,254 Shares in AbbVie Inc. $ABBV Purchased by North Dallas Bank & Trust Co. - MarketBeat
Deutsche Bank AG Raises Position in AbbVie Inc. $ABBV - MarketBeat
Novartis, AbbVie Lose Bid To Halt Wash. 340B Pharmacy Law - Law360
NICE backs AbbVie’s Aquipta for acute migraine treatment - The Pharma Letter
AbbVie Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
AbbVie (ABBV) Is Proving the Post-Humira Story Is About Skyrizi, Rinvoq, and Portfolio Depth - AlphaStreet
ABBV: Growth driven by immunology, oncology, neuroscience, and obesity, with robust pipeline progress - TradingView
7 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), GMR Solutions, Inc. Class A (GMRS) and Cullinan Management (CGEM) - The Globe and Mail
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Inc. stock (US00287Y1091): FDA decision and pipeline catalysts keep focus on growth - AD HOC NEWS
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month? - The Globe and Mail
Inflammatory Bowel Disease Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | AbbVie, Janssen Pharma, Abivax, Morphic Therapeutic, Eli Lilly, Gilead - Barchart.com
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 - Investing News Network
Is AbbVie Stock The Right Defensive Pick In This Volatile Market? - Trefis
AbbVie brings new blood cancer trial results to European doctors - Stock Titan
AbbVie, UnitedHealth, Sabra Health Care And A Consumer Defensive Stock On CNBC's 'Final Trades' - Benzinga
AbbVie Stock Price Target $350: Why TIKR Model Shows Around 54% Upside From Here - TIKR.com
Clearbridge Investments LLC Sells 204,014 Shares of AbbVie Inc. $ABBV - MarketBeat
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? - The Globe and Mail
ING Groep NV Trims Stock Position in AbbVie Inc. $ABBV - MarketBeat
DB&C Advisors LLC Purchases New Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Capital International Investors - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Capital World Investors - MarketBeat
Capital Research Global Investors Acquires 177,370 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Capital International Sarl - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Dearborn Partners LLC - MarketBeat
Capital Group Private Client Services Inc. Purchases 6,065 Shares of AbbVie Inc. $ABBV - MarketBeat
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):